Advertisement

Topics

MyoKardia Shares Skyrocket On Promising Phase II Data In HCM

13:50 EDT 7 Aug 2017 | SCRIP

Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet...

      

Related Stories

 

Original Article: MyoKardia Shares Skyrocket On Promising Phase II Data In HCM

NEXT ARTICLE

More From BioPortfolio on "MyoKardia Shares Skyrocket On Promising Phase II Data In HCM"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...